

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION *
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

PROFIT WARNING

This announcement is made by Biosino Bio-Technology and Science Incorporation* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment with reference to the unaudited consolidated management accounts of the Group, it is expected that the Group will record a loss for the three months ended 31 March 2018 (the “**Reporting Period**”) as compared to the corresponding three months ended 31 March 2017 despite there is an increase in revenue. Such loss is mainly attributable to (i) an increase in cost of sales due to a change in product mix; and (ii) an increase in administrative expenses for coping with the business and market expansion of the Group.

Nevertheless, the Board is of the view that such loss has no material adverse impact on the business operations of the Group. The financial position of the Group remains sound.

The financial information contained in this announcement is only a preliminary assessment by the Board based on the information currently available to the Company and is subject to possible adjustments upon further review. Further information and other details of the Group's financial performance for the Reporting Period will be announced in the forthcoming first quarterly results announcement in May 2018.

* For identification purposes only

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation*
Tung Woon Cheung, Eric
Company Secretary

Beijing, the PRC, 27 April 2018

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice-chairman and non-executive Director

Dr. Bi Lijun (畢利軍博士)

Vice-chairman and executive Director

Mr. Chen Jintian (陳錦添先生)

Executive Director

Dr. Xu Cunmao (許存茂博士)

Non-executive Director

Mr. Hou Quanmin (侯全民先生)

Independent non-executive Directors

Dr. Zheng Yongtang (鄭永唐博士), Dr. Hu Canwu Kevin (胡燦武博士) and Mr. Wang Daixue (王代雪先生)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.